Profit, not altruism, is pushing health insurers to champion routine childhood vaccines as MAHA returns to the political arena. Where public health agencies sound cautious, actuarial tables speak bluntly: one child with microangiopathic hemolytic anemia means plasma exchange, intensive care, and high litigation exposure, all booked as pure loss on an insurer’s balance sheet.
Insurers argue that a stable immunization schedule functions like risk pooling in its purest form, spreading the cost of antigens and cold-chain logistics to avoid the spike of thrombotic microangiopathy claims that follow outbreaks. Underwriting teams point to classic epidemiology terms—herd immunity and basic reproduction number—as if they were line items, showing that even modest reductions in pediatric coverage can trigger clusters of infection that raise MAHA incidence.
What looks like a culture war over parental choice is, for payers, a closed-loop calculation. Vaccines are cheap. Hemolysis workups, renal replacement therapy, and long rehabilitation are not. By backing pediatricians who refuse to loosen the schedule and by tying reimbursement to adherence, insurers are building a quiet moat around their medical-loss ratios, turning syringes and consent forms into instruments of balance-sheet defense.
